Xeltis’ aXess Vascular Graft Development Receives Funding From European Innovation Council

August 14, 2023—Xeltis, a developer of living implants to restore cardiovascular function that is headquartered in Eindhoven, the Netherlands, announced the closing of an additional €12.5 million in funding from the European Innovation Council (EIC) Fund. The company advised that this extension from EIC and the closure of a Series D2 financing round announced in February 2023 brings the total amount raised to €44.5 million.

According to the company, the additional funding will support the continued clinical development of Xeltis’ implants including the first-in-human (FIH) trial of its aXess vascular graft for patients with chronic kidney disease requiring hemodialysis and an ongoing pivotal trial for aXess that is enrolling patients across Europe. The EIC Accelerator funding will also be used to advance Xeltis’ coronary artery bypass graft program.

Xeltis stated that its endogenous tissue restoration platform utilizes an polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. The aXess implantable blood vessel for hemodialysis vascular access is the company’s most advanced product currently under clinical development.

Earlier this year, Xeltis announced 6-month data from the aXess-FIH study were presented by Principal Investigator Professor Matteo Tozzi, MD, at the 13th Congress of the Vascular Access Society held in Porto, Portugal, on April 27-29, 2023.